Skip to main content

Table 2 Clinical, survival and treatment data of EBV + TNK-cell lymphoproliferative disease

From: Prognostic implication of morphology, cyclinE2 and proliferation in EBV-associated T/NK lymphoproliferative disease in non-immunocompromised hosts

No Ohshima category* Histo Sex Ethnicity Age (yrs) Tissue type GEP HLH Treatment Follow up OS (mth)
1 A1 P M Indonesian 3.4 BM No + HLH -P Alive 55
2 A1 P M Chinese 13.1 BM No + HLH-P, AHCT Dead (AHCT complications) 48
3 A1 P M Vietnamese 24.8 BM No + Chemo Alive 6
4 A2 P F Chinese 5.3 BM No + HLH-P, AHCT Alive 64
5 A2 P M Chinese 1.4 Skin Yes + HLH-P , AHCT Alive (graft rejection) 95
6 A2 P F Indonesian 6.1 BM No + HLH-P Alive 31
7 A2 P M Chinese 16.7 LN Yes - Steroids, AHCT Dead 14
8 A1 or A2 P M Japanese 4 liver No + AHCT Alive 94.4
9 A1 or A2 P F Japanese 19 BM No - AHCT Alive 9.2
10 A1 or A2 P F Japanese 19 BM No + Chemo Alive 32.5
11 A1 or A2 P F Japanese 39 Skin No - Chemo Dead 21.8
12 A3 M F Vietnamese 16.4 BM No + HLH-P Dead 0.4
13 A3 M F Chinese 4.8 BM No + HLH-P Alive 21
14 B M M Indonesian 13.3 BM No + HLH -P Dead 0.83
15 B M M Indonesian 20.9 BM No + HLH -P Dead 2
16 B M F Chinese 9.5 LN Yes + Supportive Dead 1
17 B M M Chinese 18.7 LN Yes + HLH -P Dead 1.16
18 B M M Vietnamese 1 BM No + HLH-P NA NA
19 B M M Filipino 7.6 BM No + HLH-P Dead 1
20 B M F Chinese 19.3 BM No + HLH-P Dead 0.1
21 B M F Japanese 48 BM No + Chemo, AHCT Dead 2.2
22 A3 or B M M Others 18.3 BM No NA Supportive Dead 0.7
  1. Abbreviations: M male, F female, Histo histology, P polymorphic, M monomorphic, HLH-P 2004 Histiocytic Lymphohistiocytosis protocol, AHCT Allogeneic hematopoietic cell transplant, + present, absent, TCR Clonality for TCRG gene, R rearranged, NR not rearranged, NA not available, OS overall survival, LN lymph node, BM bone marrow, Chemo chemotherapy. *Categorization of EBV-associated T/NK LPD in children proposed by Ohshima et al. [13].